Exchange: NASDAQ·Updated 07:00 PM EDT
BIIB logo

BIIBBiogen Inc

$196.58
$2.09
(1.05%)
Today
Closed $196.58
$0.13
(0.07%)
After Hours
EarningsJul 29
Mkt Cap$29.02B
Vol1.73M
News
all
press releases
Denali to Sell Priority Review Voucher for $195M Cash Boost
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
Zacks
News Placeholder
More News
News Placeholder
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's disease.read more...
Benzinga
News Placeholder
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.read more...
Benzinga
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB PR Newswire NEW YORK, June 18, 2026 NEW YORK, June 18, 2026 /PRNewswire/ --Pomerantz LLP is...
PR Newswire
News Placeholder
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
Zacks
News Placeholder
BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal
The deal includes an upfront payment plus milestone payments tied primarily to clinical and regulatory successes.
Stocktwits
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB PR Newswire NEW YORK, June 11, 2026 NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is...
PR Newswire
News Placeholder
This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst ratings page for full changes and other stock views.read more...
Benzinga
News Placeholder
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
Zacks
News Placeholder
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. (Biogen or the Company) (NASDAQ: BIIB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.